Related Experiment Video
Updated: May 1, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
19.4K
New biomarkers in prostate cancer
Oncology (Williston Park, N.Y.)
|April 8, 2014
Summary
New prostate cancer (PCa) biomarkers are emerging to improve upon prostate-specific antigen (PSA) testing. These advanced assays, driven by genomic technologies, offer better diagnosis, prognosis, and treatment selection for PCa patients.
Area of Science:
- Oncology
- Biomarker Discovery
- Genomic Medicine
Background:
- Prostate cancer (PCa) is the most common male cancer in the US.
- Prostate-specific antigen (PSA) is a widely used but imperfect biomarker for PCa screening.
- Limitations in PSA sensitivity and specificity necessitate improved diagnostic tools.
Purpose of the Study:
- To review recent advances in prostate cancer biomarker discovery.
- To discuss the integration of novel biomarkers into clinical practice.
- To explore the implications of new biomarkers for improving PCa management.
Main Methods:
- Review of emerging serum-, urine-, and tissue-based PCa biomarker assays.
- Discussion of genomic technologies facilitating biomarker development.
- Analysis of commercially available biomarkers for diagnosis, prediction, and prognosis.
Main Results:
- A new generation of PCa biomarkers is emerging, offering potential improvements over PSA.
- Genomic technologies are key drivers in identifying and developing these novel biomarkers.
- Several new biomarkers are available for clinical use, aiding in disease stratification and management.
Conclusions:
- Novel biomarkers hold promise to supplement or replace PSA testing for prostate cancer.
- Genomic insights are crucial for understanding individual tumor biology and guiding biomarker development.
- These advancements are poised to significantly enhance the clinical management of prostate cancer.
